Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Peptic Ulcer

Free Subscription Articles published in Helicobacter Retrieve available abstracts of 238 articles: HTML format

Single Articles

November 2023
1. MELO J, Cavadas B, Pereira L, Figueiredo C, et al
   Transcriptomic remodeling of gastric cells by Helicobacter pylori outer membrane vesicles.
   Helicobacter. 2023 Nov 23:e13031. doi: 10.1111/hel.13031.
   PubMed     Abstract available
   
   
   
2. LIM NR, Kim J, Chung WC
   Recurrence of Helicobacter pylori following successful eradication and clinical outcomes in Korean patients.
   Helicobacter. 2023 Nov 20:e13036. doi: 10.1111/hel.13036.
   PubMed     Abstract available
   
   
   
3. XU W, Yang B, Lin L, Lin Q, et al
   Antibiotic resistance of Helicobacter pylori in Chinese children: A multicenter study from 2016 to 2023.
   Helicobacter. 2023 Nov 20:e13038. doi: 10.1111/hel.13038.
   PubMed     Abstract available
   
   
   
4. ZHOU BG, Jiang X, Ding YB, She Q, et al
   Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
   Helicobacter. 2023 Nov 20:e13040. doi: 10.1111/hel.13040.
   PubMed     Abstract available
   
   
   
5. VERNON-ROBERTS A, Premaratne M, Wright R, Keenan JI, et al
   Profile of Helicobacter pylori infections among children in the South Island of New Zealand (2010-2021).
   Helicobacter. 2023 Nov 20:e13037. doi: 10.1111/hel.13037.
   PubMed     Abstract available
   
   
   
6. YUNLE K, Tong W, Jiyang L, Guojun W, et al
   Advances in Helicobacter pylori vaccine research: From candidate antigens to adjuvants-A review.
   Helicobacter. 2023 Nov 16:e13034. doi: 10.1111/hel.13034.
   PubMed     Abstract available
   
   
   
7. FANI T, Ioannis TG
   Letter to the Editor regarding the article: "Forty years of Helicobacter pylori infection and changes in findings at esophagogastroduodenoscopy".
   Helicobacter. 2023 Nov 13:e13035. doi: 10.1111/hel.13035.
   PubMed    
   
   
   
8. LEE CT, Wu CT, Chang WL, Yang EH, et al
   The nonadherence and risk factors of eradication failure by sequential therapy as first-line anti-Helicobacter pylori treatment in real-world clinical practice.
   Helicobacter. 2023 Nov 10:e13033. doi: 10.1111/hel.13033.
   PubMed     Abstract available
   
   
   October 2023
9. YE J, Feng T, Su L, Li J, et al
   Interactions between Helicobacter pylori infection and host metabolic homeostasis: A comprehensive review.
   Helicobacter. 2023 Oct 23:e13030. doi: 10.1111/hel.13030.
   PubMed     Abstract available
   
   
   
10. YOUSEFI M, Rezaei S, Khoshbaten M, Sarmasti M, et al
    Cost-effectiveness analysis of different screening strategies for helicobacter pylori infection in Iran: A model-based evaluation.
    Helicobacter. 2023 Oct 15:e13027. doi: 10.1111/hel.13027.
    PubMed     Abstract available
    
    
    
11. GAO W, Zhu M, Yin Y, Zhang X, et al
    Efficacy and safety of minocycline quadruple therapy for Helicobacter pylori eradication: A meta-analysis of RCTs.
    Helicobacter. 2023 Oct 15:e13022. doi: 10.1111/hel.13022.
    PubMed     Abstract available
    
    
    
12. TAN W, Liu Y, Shi Z, Zheng B, et al
    Information quality of videos related to Helicobacter pylori infection on TikTok: Cross-sectional study.
    Helicobacter. 2023 Oct 12:e13029. doi: 10.1111/hel.13029.
    PubMed     Abstract available
    
    
    
13. OKIMOTO T, Ando T, Sasaki M, Ono S, et al
    Antimicrobial-resistant Helicobacter pylori in Japan: Report of nationwide surveillance for 2018-2020.
    Helicobacter. 2023 Oct 12:e13028. doi: 10.1111/hel.13028.
    PubMed     Abstract available
    
    
    
14. O'CONNOR HJ
    Forty years of Helicobacter pylori infection and changes in findings at esophagogastroduodenoscopy.
    Helicobacter. 2023 Oct 11:e13026. doi: 10.1111/hel.13026.
    PubMed     Abstract available
    
    
    
15. WU S, Chen Y, Chen Z, Wei F, et al
    Reactive oxygen species and gastric carcinogenesis: The complex interaction between Helicobacter pylori and host.
    Helicobacter. 2023 Oct 5:e13024. doi: 10.1111/hel.13024.
    PubMed     Abstract available
    
    
    
16. DORE MP, Erre GL, Piroddu J, Pes GM, et al
    Helicobacter pylori infection and rheumatoid arthritis as risk enhancers' factors for atherosclerotic cardiovascular diseases.
    Helicobacter. 2023 Oct 4:e13025. doi: 10.1111/hel.13025.
    PubMed     Abstract available
    
    
    September 2023
17. VESGA FJ, Beltran-Benavides AR, Marquez-Duque AM, Venegas C, et al
    Helicobacter pylori virulence genotypes in Bogota River and wastewater treatment plants in Colombia.
    Helicobacter. 2023 Sep 27:e13023. doi: 10.1111/hel.13023.
    PubMed     Abstract available
    
    
    
18. RATANA-AMORNPIN S, Sanglutong L, Eiamsitrakoon T, Siramolpiwat S, et al
    Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan.
    Helicobacter. 2023 Sep 18:e13019. doi: 10.1111/hel.13019.
    PubMed     Abstract available
    
    
    
19. LI Y, Ouyang Y, He C
    Research trends on the relationship between Helicobacter pylori and microbiota: A bibliometric analysis.
    Helicobacter. 2023 Sep 11:e13021. doi: 10.1111/hel.13021.
    PubMed     Abstract available
    
    
    
20. ZHANG X, Zhang K, Yan L, Wang P, et al
    The role of toll-like receptors in immune tolerance induced by Helicobacter pylori infection.
    Helicobacter. 2023 Sep 10:e13020. doi: 10.1111/hel.13020.
    PubMed     Abstract available
    
    
    
21. GONG X, Shen L, Xie J, Liu D, et al
    Helicobacter pylori infection reduces the efficacy of cancer immunotherapy: A systematic review and meta-analysis.
    Helicobacter. 2023 Sep 3:e13011. doi: 10.1111/hel.13011.
    PubMed     Abstract available
    
    
    August 2023
22. LIN K, Huang L, Wang Y, Li K, et al
    Efficacy of genotypic susceptibility-guided tailored therapy for Helicobacter pylori infection: A systematic review and single arm meta-analysis.
    Helicobacter. 2023 Aug 27:e13015. doi: 10.1111/hel.13015.
    PubMed     Abstract available
    
    
    
23. QUACH DT, Vilaichone RK, Luu MN, Lee YY, et al
    Real-world practice of Helicobacter pylori management: A survey among physicians in Southeast Asia.
    Helicobacter. 2023 Aug 27:e13018. doi: 10.1111/hel.13018.
    PubMed     Abstract available
    
    
    
24. YU Z, Zhang X, Zhao Q, Yan X, et al
    Urolithin B alleviates Helicobacter pylori-induced inflammation and oxidative stress in mice.
    Helicobacter. 2023 Aug 25:e13016. doi: 10.1111/hel.13016.
    PubMed     Abstract available
    
    
    
25. ISMAIL NI, Nawawi KNM, Hsin DCC, Hao KW, et al
    Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double-blind, placebo-controlled trial.
    Helicobacter. 2023 Aug 23:e13017. doi: 10.1111/hel.13017.
    PubMed     Abstract available
    
    
    
26. ZHU F, Zhang X, Li P, Zhu Y, et al
    Effect of Helicobacter pylori eradication on gastric precancerous lesions: A systematic review and meta-analysis.
    Helicobacter. 2023 Aug 21:e13013. doi: 10.1111/hel.13013.
    PubMed     Abstract available
    
    
    
27. SU NY, Shi Q, Mei H, Hu J, et al
    Efficacy and safety of vonoprazan-based dual therapy and esomeprazole-based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis.
    Helicobacter. 2023 Aug 10:e13003. doi: 10.1111/hel.13003.
    PubMed     Abstract available
    
    
    
28. BAWAND R, Ghiasian M, Samadyan M, Qaderi S, et al
    Association of Helicobacter pylori with migraine headaches and the effects of this infection and its eradication on the migraine characteristics in adults: A comprehensive systematic review and meta-analysis.
    Helicobacter. 2023 Aug 2:e13010. doi: 10.1111/hel.13010.
    PubMed     Abstract available
    
    
    July 2023
29. DU RC, Ouyang YB, Lu NH, Hu Y, et al
    Research trends on vonoprazan-based therapy for Helicobacter pylori eradication: A bibliometric analysis from 2015 to 2023.
    Helicobacter. 2023 Jul 29:e13012. doi: 10.1111/hel.13012.
    PubMed     Abstract available
    
    
    
30. NGUYEN TC, Le GKN, Pham DTH, Pham BV, et al
    Antibiotic resistance and heteroresistance in Helicobacter pylori isolates from symptomatic Vietnamese children: A prospective multicenter study.
    Helicobacter. 2023 Jul 27:e13009. doi: 10.1111/hel.13009.
    PubMed     Abstract available
    
    
    
31. LIMA IS, da Silva TM, Weiss S, Homuth G, et al
    Genome-wide association study of Helicobacter pylori serological status in Latin American children.
    Helicobacter. 2023 Jul 27:e13008. doi: 10.1111/hel.13008.
    PubMed     Abstract available
    
    
    
32. DU RC, Zhang Y, Wang MH, Lu NH, et al
    TikTok and Bilibili as sources of information on Helicobacter pylori in China: A content and quality analysis.
    Helicobacter. 2023 Jul 15:e13007. doi: 10.1111/hel.13007.
    PubMed     Abstract available
    
    
    
33. KOTILEA K, Iliadis E, Nguyen J, Salame A, et al
    Antibiotic resistance, heteroresistance, and eradication success of Helicobacter pylori infection in children.
    Helicobacter. 2023 Jul 4:e13006. doi: 10.1111/hel.13006.
    PubMed     Abstract available
    
    
    June 2023
34. HASSAN SS, Nader M, Nagy M, Mohamed M, et al
    Antimicrobial screening involving Helicobacter pylori of nano-therapeutic compounds based on the amoxicillin antibiotic drug.
    Helicobacter. 2023 Jun 30:e13004. doi: 10.1111/hel.13004.
    PubMed     Abstract available
    
    
    
35. ZHANG Y, Zhao Z, Fu W, Ding S, et al
    The expression and function of the B7 family in Helicobacter pylori infection and gastric carcinogenesis process.
    Helicobacter. 2023 Jun 29:e12999. doi: 10.1111/hel.12999.
    PubMed     Abstract available
    
    
    
36. ZHANG Z, Chen X, Li B, Xia T, et al
    Helicobacter pylori induces urease subunit B-specific CD8(+) T cell responses in infected individuals via cytosolic pathway of cross-presentation.
    Helicobacter. 2023 Jun 29:e13005. doi: 10.1111/hel.13005.
    PubMed     Abstract available
    
    
    
37. BARREYRO FJ, Maiorana F, Caronia MV, Elizondo K, et al
    Association between genetic polymorphisms of NOD1, Interleukin-1B, and cagA strain with low-grade duodenal eosinophilia in Helicobacter pylori-related dyspepsia.
    Helicobacter. 2023 Jun 23:e13002. doi: 10.1111/hel.13002.
    PubMed     Abstract available
    
    
    
38. ISMAIL M, Majaliwa ND, Vale FF, Cumbana R, et al
    Molecular detection of Helicobacter pylori and its genotypic antimicrobial resistance patterns in dyspeptic Mozambican patients.
    Helicobacter. 2023 Jun 20:e13000. doi: 10.1111/hel.13000.
    PubMed     Abstract available
    
    
    
39. KATSANDE PM, Nguyen VD, Nguyen TLP, Nguyen TKC, et al
    Prophylactic immunization to Helicobacter pylori infection using spore vectored vaccines.
    Helicobacter. 2023 Jun 14:e12997. doi: 10.1111/hel.12997.
    PubMed     Abstract available
    
    
    
40. LEE SY, Kim JH, Sung IK, Park HS, et al
    Twice-daily intake of bismuth-based quadruple therapy for first-line Helicobacter pylori eradication: A retrospective study on 10-day, 14-day, and half-dose antibiotic therapy.
    Helicobacter. 2023 Jun 9:e12998. doi: 10.1111/hel.12998.
    PubMed     Abstract available
    
    
    May 2023
41. JIANG F, Ju C, Guo CG, Cheung KS, et al
    Risk of hospitalization for upper gastrointestinal bleeding in Helicobacter pylori eradicated patients newly started on warfarin or direct oral anticoagulants: A population-based cohort study.
    Helicobacter. 2023 May 29:e12990. doi: 10.1111/hel.12990.
    PubMed     Abstract available
    
    
    
42. ZENG R, Li X, Wang F, Xie J, et al
    Reinforced medication adherence improves Helicobacter pylori eradication rate in developing countries: A systematic review and meta-analysis of randomized controlled trials.
    Helicobacter. 2023 May 17:e12989. doi: 10.1111/hel.12989.
    PubMed     Abstract available
    
    
    
43. HU J, Mei H, Su NY, Sun WJ, et al
    Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China.
    Helicobacter. 2023 May 9:e12970. doi: 10.1111/hel.12970.
    PubMed     Abstract available
    
    
    
44. KARAYIANNIS I, Martinez-Gonzalez B, Kontizas E, Kokkota AV, et al
    Induction of MMP-3 and MMP-9 expression during Helicobacter pylori infection via MAPK signaling pathways.
    Helicobacter. 2023 May 4:e12987. doi: 10.1111/hel.12987.
    PubMed     Abstract available
    
    
    
45. WANG R, Huang S, Gan P, Pan X, et al
    States and hotspots in Helicobacter pylori research from 2002 to 2021: A bibliometric analysis.
    Helicobacter. 2023 May 3:e12986. doi: 10.1111/hel.12986.
    PubMed     Abstract available
    
    
    April 2023
46. MCNULTY CAM
    The first 5 years of Helicobacter pylori research-With an emphasis on the United Kingdom.
    Helicobacter. 2023 Apr 27:e12982. doi: 10.1111/hel.12982.
    PubMed     Abstract available
    
    
    
47. LI M, Gao N, Wang S, Guo Y, et al
    Bibliometric analysis of Helicobacter pylori resistance-from 2002 to 2022.
    Helicobacter. 2023 Apr 27:e12983. doi: 10.1111/hel.12983.
    PubMed     Abstract available
    
    
    
48. ZANG H, Wang J, Wang H, Guo J, et al
    Metabolic alterations in patients with Helicobacter pylori-related gastritis: The H. pylori-gut microbiota-metabolism axis in progression of the chronic inflammation in the gastric mucosa.
    Helicobacter. 2023 Apr 25:e12984. doi: 10.1111/hel.12984.
    PubMed     Abstract available
    
    
    
49. KIM JS, Ko W, Chung JW, Kim TH, et al
    Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double-blind, active-controlled study.
    Helicobacter. 2023 Apr 21:e12977. doi: 10.1111/hel.12977.
    PubMed     Abstract available
    
    
    
50. HAN X, Yu X, Gao X, Wang X, et al
    Quantitative PCR of string-test collected gastric material: A feasible approach to detect Helicobacter pylori and its resistance against clarithromycin and levofloxacin for susceptibility-guided therapy.
    Helicobacter. 2023 Apr 17:e12985. doi: 10.1111/hel.12985.
    PubMed     Abstract available
    
    
    
51. HU S, Zhou Y, Deng Y, Bo Y, et al
    Characteristics of phenotypic antibiotic resistance of Helicobacter pylori and its correlation with genotypic antibiotic resistance: A retrospective study in Ningxia.
    Helicobacter. 2023 Apr 11:e12960. doi: 10.1111/hel.12960.
    PubMed     Abstract available
    
    
    
52. SOH H, Kim N, Moon J, Lee HM, et al
    Gastric mucosal swab as an alternative to biopsy for Helicobacter pylori detection.
    Helicobacter. 2023 Apr 7:e12980. doi: 10.1111/hel.12980.
    PubMed     Abstract available
    
    
    
53. YU H, Li J, Liu X, Chen Z, et al
    Helicobacter pylori bacteremia presenting as seizure and unconsciousness: The brief case.
    Helicobacter. 2023 Apr 5:e12973. doi: 10.1111/hel.12973.
    PubMed     Abstract available
    
    
    
54. ZENG R, Xie Y
    Inquiry about methodology used to isolate multiple Helicobacter pylori strains from the same patient.
    Helicobacter. 2023 Apr 3:e12981. doi: 10.1111/hel.12981.
    PubMed    
    
    
    
55. KOSUNEN TU, Nieminen AA, Kokkola A, Arkkila P, et al
    Incidence of gastrointestinal malignancies increases in persons received eradication therapy for Helicobacter pylori: A cohort study.
    Helicobacter. 2023 Apr 3:e12979. doi: 10.1111/hel.12979.
    PubMed     Abstract available
    
    
    
56. COLLIN A, Mion F, Kefleyesus A, Beets C, et al
    Critical appraisal of international guidelines for the management of Helicobacter pylori infection in case of dyspepsia.
    Helicobacter. 2023;28:e12952.
    PubMed     Abstract available
    
    
    March 2023
57. XIE Y, Hu Y, Zhu Y, Wang H, et al
    Colloidal bismuth pectin-containing quadruple therapy as the first-line treatment of Helicobacter pylori infection: A multicenter, randomized, double-blind, non-inferiority clinical trial.
    Helicobacter. 2023 Mar 31:e12978. doi: 10.1111/hel.12978.
    PubMed     Abstract available
    
    
    
58. KWON YM, Kim SJ, Lee JG, Lee SP, et al
    Effects of prior antibiotic use on clarithromycin resistance in Helicobacter pylori.
    Helicobacter. 2023 Mar 28:e12974. doi: 10.1111/hel.12974.
    PubMed     Abstract available
    
    
    
59. SUN L, Zheng H, Qiu M, Hao S, et al
    Helicobacter pylori infection and risk of cardiovascular disease.
    Helicobacter. 2023 Mar 28:e12967. doi: 10.1111/hel.12967.
    PubMed     Abstract available
    
    
    
60. LYU T, Cheung KS, Deng Z, Ni L, et al
    Whole genome sequencing reveals novel genetic mutations of Helicobacter pylori associating with resistance to clarithromycin and levofloxacin.
    Helicobacter. 2023 Mar 25:e12972. doi: 10.1111/hel.12972.
    PubMed     Abstract available
    
    
    
61. IKEDA N, Shoji H, Ikuse T, Ohkawa N, et al
    A case of neonatal thrombocytopenia due to maternal Helicobacter pylori-associated immune thrombocytopenia.
    Helicobacter. 2023 Mar 23:e12976. doi: 10.1111/hel.12976.
    PubMed     Abstract available
    
    
    
62. KIM SB, Kim N, Park J, Hwang IC, et al
    Preventive effect of Helicobacter pylori eradication on the coronary heart diseases depending on age and sex with a median follow-up of 51 months.
    Helicobacter. 2023 Mar 22:e12969. doi: 10.1111/hel.12969.
    PubMed     Abstract available
    
    
    
63. ERGENC M, Uprak TK
    YouTube as a source of information on Helicobacter pylori: Content and quality analysis.
    Helicobacter. 2023 Mar 21:e12971. doi: 10.1111/hel.12971.
    PubMed     Abstract available
    
    
    
64. SHENG C, Sun L, Lyu Z, Li L, et al
    Development of a modified ABC method among Helicobacter pylori infected but serum pepsinogen test-negative individuals.
    Helicobacter. 2023 Mar 20:e12966. doi: 10.1111/hel.12966.
    PubMed     Abstract available
    
    
    
65. ANTUNES R, Oleastro M, Nogueira JP, Lopes AI, et al
    Time trend prevalence of helicobacter pylori infection and endoscopic findings in symptomatic children in Portugal: A retrospective study based on three time points in 2009, 2014, and 2019.
    Helicobacter. 2023 Mar 10:e12963. doi: 10.1111/hel.12963.
    PubMed     Abstract available
    
    
    
66. YU T, Lu T, Deng W, Yao D, et al
    Microbiome and function alterations in the gastric mucosa of asymptomatic patients with Helicobacter pylori infection.
    Helicobacter. 2023 Mar 8:e12965. doi: 10.1111/hel.12965.
    PubMed     Abstract available
    
    
    February 2023
67. REN X, Shi Y, Suo B, Yao X, et al
    Individualized diagnosis and eradication therapy for Helicobacter pylori infection based on gene detection of clarithromycin resistance in stool specimens: A systematic review and meta-analysis.
    Helicobacter. 2023 Feb 24:e12958. doi: 10.1111/hel.12958.
    PubMed     Abstract available
    
    
    
68. KAJIHARA Y, Shimoyama T, Mizuki I
    Evaluation of the effects of a proton pump inhibitor on Helicobacter pylori stool antigen testing.
    Helicobacter. 2023 Feb 24:e12961. doi: 10.1111/hel.12961.
    PubMed     Abstract available
    
    
    
69. ARINO-PEREZ I, Martinez-Dominguez SJ, Alfaro Almajano E, Carrera-Lasfuentes P, et al
    Mistakes in the diagnosis and treatment of Helicobacter pylori infection in daily clinical practice.
    Helicobacter. 2023 Feb 24:e12957. doi: 10.1111/hel.12957.
    PubMed     Abstract available
    
    
    
70. HE T, Zhang F, Zhang J, Wei S, et al
    UreB immunodominant epitope-specific CD8(+) T-cell responses were beneficial in reducing gastric symptoms in Helicobacter pylori-infected individuals.
    Helicobacter. 2023 Feb 24:e12959. doi: 10.1111/hel.12959.
    PubMed     Abstract available
    
    
    
71. MACEDO SILVA V, Lima Capela T, Freitas M, Boal Carvalho P, et al
    A "new" option in Helicobacter pylori eradication: High-dose amoxicillin dual therapy outperforms bismuth quadruple therapy in a high dual resistance setting.
    Helicobacter. 2023 Feb 24:e12962. doi: 10.1111/hel.12962.
    PubMed     Abstract available
    
    
    
72. ZHAI K, Gong Y, Sun L, He L, et al
    DNA starvation/stationary phase protection protein of Helicobacter pylori as a potential immunodominant antigen for infection detection.
    Helicobacter. 2023 Feb 12:e12955. doi: 10.1111/hel.12955.
    PubMed     Abstract available
    
    
    
73. ZHANG Y, Suo B, Tian X, Zhang H, et al
    New regimens as first-line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: A randomized controlled trial.
    Helicobacter. 2023 Feb 8:e12956. doi: 10.1111/hel.12956.
    PubMed     Abstract available
    
    
    
74. BAILEY KS, Brown HE, Lekic V, Pradeep K, et al
    Helicobacter pylori treatment knowledge, access and barriers: A cross-sectional study.
    Helicobacter. 2023 Feb 7:e12954. doi: 10.1111/hel.12954.
    PubMed     Abstract available
    
    
    
75. GUAN JL, Han YY, Wang MR, Xia SH, et al
    Impact of body size on efficacy of high-dose dual therapy for Helicobacter pylori eradication.
    Helicobacter. 2023 Feb 3:e12953. doi: 10.1111/hel.12953.
    PubMed     Abstract available
    
    
    January 2023
76. HASSUNA NA, Hussien SS, Abdelhakeem M, Aboalela A, et al
    Regulatory B cells (Bregs) in Helicobacter pylori chronic infection.
    Helicobacter. 2023 Jan 20:e12951. doi: 10.1111/hel.12951.
    PubMed     Abstract available
    
    
    
77. GAO W, Xu Y, Liu J, Wang X, et al
    A real-world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of Helicobacter pylori infection in special populations with penicillin allergy or failed in previous amoxicillin-containing therapies.
    Helicobacter. 2023 Jan 17:e12947. doi: 10.1111/hel.12947.
    PubMed     Abstract available
    
    
    
78. HAN Z, Liu J, Zhang W, Kong Q, et al
    Cardia and non-cardia gastric cancer risk associated with Helicobacter pylori in East Asia and the West: A systematic review, meta-analysis, and estimation of population attributable fraction.
    Helicobacter. 2023 Jan 16:e12950. doi: 10.1111/hel.12950.
    PubMed     Abstract available
    
    
    
79. WANG Y, Dai X, Gao C, Yang X, et al
    Network meta-analysis of different dosages of esomeprazole and rabeprazole for the treatment of Helicobacter pylori.
    Helicobacter. 2023 Jan 16:e12948. doi: 10.1111/hel.12948.
    PubMed     Abstract available
    
    
    
80. DUAN M, Li Y, Liu J, Zhang W, et al
    Transmission routes and patterns of helicobacter pylori.
    Helicobacter. 2023 Jan 16:e12945. doi: 10.1111/hel.12945.
    PubMed     Abstract available
    
    
    
81. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Persistent advanced periductal fibrosis is and helicobacter pylori infection in post-treatment of opisthorchiasis: Correspondence.
    Helicobacter. 2023 Jan 12:e12949. doi: 10.1111/hel.12949.
    PubMed    
    
    
    
82. ZHANG W, Gui Q, Chen J, Yu D, et al
    Intravenous metronidazole-, levofloxacin-containing triple therapy for treating patients with Helicobacter pylori-related active peptic ulcer complications: A pilot study.
    Helicobacter. 2023 Jan 12:e12946. doi: 10.1111/hel.12946.
    PubMed     Abstract available
    
    
    
83. AMALIA R, Panenggak NSR, Doohan D, Rezkitha YAA, et al
    A comprehensive evaluation of an animal model for Helicobacter pylori-associated stomach cancer: Fact and controversy.
    Helicobacter. 2023 Jan 10:e12943. doi: 10.1111/hel.12943.
    PubMed     Abstract available
    
    
    December 2022
84. ZHENG SY, Zhu L, Wu LY, Liu HR, et al
    Helicobacter pylori-positive chronic atrophic gastritis and cellular senescence.
    Helicobacter. 2022 Dec 20:e12944. doi: 10.1111/hel.12944.
    PubMed     Abstract available
    
    
    
85. HAN Z, Li Y, Li Y
    Helicobacter pylori, gastrointestinal microbiota, and immunotherapy.
    Helicobacter. 2022 Dec 7:e12942. doi: 10.1111/hel.12942.
    PubMed    
    
    
    
86. LEE JW, Kim N, Choi SI, Jang JY, et al
    Prevalence and trends of multiple antimicrobial resistance of Helicobacter pylori in one tertiary hospital for 20 years in Korea.
    Helicobacter. 2022 Dec 7:e12939. doi: 10.1111/hel.12939.
    PubMed     Abstract available
    
    
    
87. RAMESH P, Babu S, Ammankallu S, Codi JAK, et al
    Helicobacter pylori regulated microRNA map of human gastric cells.
    Helicobacter. 2022 Dec 5:e12941. doi: 10.1111/hel.12941.
    PubMed     Abstract available
    
    
    
88. ROKKAS T, Ekmektzoglou K, Graham DY
    Current role of tailored therapy in treating Helicobacter pylori infections. A systematic review, meta-analysis and critical analysis.
    Helicobacter. 2022 Dec 1:e12936. doi: 10.1111/hel.12936.
    PubMed     Abstract available
    
    
    
89. LU L, Wang Y, Ye J, Han Y, et al
    Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
    Helicobacter. 2022 Dec 1:e12940. doi: 10.1111/hel.12940.
    PubMed     Abstract available
    
    
    November 2022
90. YANG H, Mou Y, Hu B
    Discussion on the common controversies of Helicobacter pylori infection.
    Helicobacter. 2022 Nov 27:e12938. doi: 10.1111/hel.12938.
    PubMed     Abstract available
    
    
    
91. JI YH, Shi YM, Hei QW, Sun JM, et al
    Evaluation of guidelines for diagnosis and treatment of Helicobacter pylori infection.
    Helicobacter. 2022 Nov 21:e12937. doi: 10.1111/hel.12937.
    PubMed     Abstract available
    
    
    
92. TIAN XL, Suo BJ, Zhang H, Lu HP, et al
    Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
    Helicobacter. 2022 Nov 14:e12935. doi: 10.1111/hel.12935.
    PubMed     Abstract available
    
    
    October 2022
93. HARA D, Okamura T, Iwaya Y, Nagaya T, et al
    Histopathologically defined intestinal metaplasia in lesser curvature of corpus prior to Helicobacter pylori eradication is a risk factor for gastric cancer development.
    Helicobacter. 2022 Oct 20:e12934. doi: 10.1111/hel.12934.
    PubMed     Abstract available
    
    
    
94. TSUDA M, Watanabe Y, Oikawa R, Watanabe R, et al
    Clinical evaluation of a novel molecular diagnosis kit for detecting Helicobacter pylori and clarithromycin-resistant using intragastric fluid.
    Helicobacter. 2022 Oct 20:e12933. doi: 10.1111/hel.12933.
    PubMed     Abstract available
    
    
    September 2022
95. CHUAH YY, Wu DC, Chuah SK, Chen KY, et al
    REAP-HP survey 2020: Comparing the real-world practice and expectation in Helicobacter pylori eradication of the Taiwanese gastroenterologists in 2015 and 2020.
    Helicobacter. 2022 Sep 25:e12931. doi: 10.1111/hel.12931.
    PubMed     Abstract available
    
    
    
96. HAN Z, Li Y, Kong Q, Liu J, et al
    Efficacy of bismuth for antibiotic-resistant Helicobacter pylori strains eradication: A systematic review and meta-analysis.
    Helicobacter. 2022 Sep 25:e12930. doi: 10.1111/hel.12930.
    PubMed     Abstract available
    
    
    
97. ZHANG Y, Li X, Shan B, Zhang H, et al
    Perspectives from recent advances of Helicobacter pylori vaccines research.
    Helicobacter. 2022 Sep 22:e12926. doi: 10.1111/hel.12926.
    PubMed     Abstract available
    
    
    
98. AZRAD M, Vazana D, On A, Paritski M, et al
    Antibiotic resistance patterns of Helicobacter pylori in North Israel - A six-year study.
    Helicobacter. 2022 Sep 15:e12932. doi: 10.1111/hel.12932.
    PubMed     Abstract available
    
    
    
99. CHOI S, Kim N, Park JH, Nam RH, et al
    Effect of Helicobacter pylori infection and its eradication on the expression of tight junction proteins in the gastric epithelium in relation to gastric carcinogenesis.
    Helicobacter. 2022 Sep 5:e12929. doi: 10.1111/hel.12929.
    PubMed     Abstract available
    
    
    August 2022
100. ARJMANDI D, Abdollahi A, Ardekani A, Razavian I, et al
     Helicobacter pylori infection and risk of multiple sclerosis: An updated meta-analysis.
     Helicobacter. 2022 Aug 31:e12927. doi: 10.1111/hel.12927.
     PubMed     Abstract available
     
     
     
101. WERNLY S, Semmler G, Volkerer A, Flamm M, et al
     Helicobacter pylori and cardiovascular risk: Only a dead Helicobacter is a good Helicobacter?
     Helicobacter. 2022 Aug 31:e12928. doi: 10.1111/hel.12928.
     PubMed     Abstract available
     
     
     
102. SHI Y, Zheng H, Guo Z, Deng R, et al
     Effect of Helicobacter pylori on immunotherapy is gaining more attention.
     Helicobacter. 2022 Aug 29:e12925. doi: 10.1111/hel.12925.
     PubMed     Abstract available
     
     
     
103. HU Y, Xu X, Ouyang YB, He C, et al
     Analysis of oral microbiota alterations induced by Helicobacter pylori infection and vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication.
     Helicobacter. 2022 Aug 29:e12923. doi: 10.1111/hel.12923.
     PubMed     Abstract available
     
     
     
104. BORDIN D, Morozov S, Plavnik R, Bakulina N, et al
     Helicobacter pylori infection prevalence in ambulatory settings in 2017-2019 in RUSSIA: The data of real-world national multicenter trial.
     Helicobacter. 2022 Aug 16:e12924. doi: 10.1111/hel.12924.
     PubMed     Abstract available
     
     
     
105. TANAKA I, Ono S, Watanabe Y, Yamamoto H, et al
     Long-term changes in aberrant DNA methylation and gastritis after Helicobacter pylori eradication focused on metachronous gastric cancer.
     Helicobacter. 2022 Aug 8:e12915. doi: 10.1111/hel.12915.
     PubMed     Abstract available
     
     
     
106. HAN YY, Long H, Lin Y, He Q, et al
     Optimized dual therapy for treatment-naive patients of Helicobacter pylori infection: A large-scale prospective, multicenter, open-label, randomized controlled study.
     Helicobacter. 2022 Aug 8. doi: 10.1111/hel.12922.
     PubMed     Abstract available
     
     
     
107. SHAO Y, Lin Y, Wang B, Miao M, et al
     Antibiotic resistance status of helicobacter pylori strains isolated from initial eradication patients in Ningbo, China, from 2017 to 2021.
     Helicobacter. 2022 Aug 8:e12920. doi: 10.1111/hel.12920.
     PubMed     Abstract available
     
     
     
108. ZHONG Z, Zhan B, Xu B, Gao H, et al
     Achieving Helicobacter pylori eradication in the primary treatment requires a deep integration of personalization and standardization.
     Helicobacter. 2022 Aug 8:e12916. doi: 10.1111/hel.12916.
     PubMed    
     
     
     
109. INAMASU Y, Ogawa M, Saito M, Harada M, et al
     Helicobacter pylori results in lysis and death after exposure to water.
     Helicobacter. 2022 Aug 8:e12921. doi: 10.1111/hel.12921.
     PubMed     Abstract available
     
     
     July 2022
110. MUNIR M, LeMaitre B, Lobo Z, Psevdos G, et al
     A 15-year review of Helicobacter pylori screening and treatment among United States Veterans.
     Helicobacter. 2022 Jul 28:e12919. doi: 10.1111/hel.12919.
     PubMed    
     
     
     
111. MOMMERSTEEG MC, Yu BT, van den Bosch TPP, von der Thusen JH, et al
     Constitutive programmed death ligand 1 expression protects gastric G-cells from Helicobacter pylori-induced inflammation.
     Helicobacter. 2022 Jul 28:e12917. doi: 10.1111/hel.12917.
     PubMed     Abstract available
     
     
     
112. GAO W, Teng G, Wang C, Xu Y, et al
     Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study i
     Helicobacter. 2022 Jul 25:e12918. doi: 10.1111/hel.12918.
     PubMed     Abstract available
     
     
     
113. CHEN MJ, Bair MJ, Chen PY, Lee JY, et al
     Declining trends of prevalence of Helicobacter pylori infection and incidence of gastric cancer in Taiwan: An updated cross-sectional survey and meta-analysis.
     Helicobacter. 2022 Jul 18:e12914. doi: 10.1111/hel.12914.
     PubMed     Abstract available
     
     
     
114. SUKRI A, Hanafiah A, Kosai NR, Mohammed Taher M, et al
     New insight on the role of Helicobacter pylori cagA in the expression of cell surface antigens with important biological functions in gastric carcinogenesis.
     Helicobacter. 2022 Jul 18:e12913. doi: 10.1111/hel.12913.
     PubMed     Abstract available
     
     
     
115. KONG Q, Li Y, Li R, Li Z, et al
     Low compliance to post-screening recommendations in a family-based Helicobacter pylori screening and treatment program: A prospective cohort study.
     Helicobacter. 2022 Jul 11:e12912. doi: 10.1111/hel.12912.
     PubMed     Abstract available
     
     
     June 2022
116. MA J, Yu M, Shao QQ, Yu XC, et al
     Both family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are cost-effective for gastric cancer prevention.
     Helicobacter. 2022 Jun 15:e12911. doi: 10.1111/hel.12911.
     PubMed     Abstract available
     
     
     
117. SOUISSI S, Makni C, Belhadj Ammar L, Bousnina O, et al
     Correlation between the intensity of Helicobacter pylori colonization and severity of gastritis: Results of a prospective study.
     Helicobacter. 2022 Jun 13:e12910. doi: 10.1111/hel.12910.
     PubMed     Abstract available
     
     
     
118. XIAO W, Ma ZS
     Influences of Helicobacter pylori infection on diversity, heterogeneity, and composition of human gastric microbiomes across stages of gastric cancer development.
     Helicobacter. 2022 Jun 9:e12899. doi: 10.1111/hel.12899.
     PubMed     Abstract available
     
     
     May 2022
119. INOKUCHI K, Mori H, Matsuzaki J, Hirata K, et al
     Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen.
     Helicobacter. 2022 May 29:e12900. doi: 10.1111/hel.12900.
     PubMed     Abstract available
     
     
     
120. AKAR M, Saticioglu IB, Karakaya E, Kayman T, et al
     Two novel sequence types of Helicobacter pylori strains: The first report from Turkey.
     Helicobacter. 2022 May 23:e12907. doi: 10.1111/hel.12907.
     PubMed    
     
     
     
121. HE C, Peng C, Xu X, Li N, et al
     Probiotics mitigate Helicobacter pylori-induced gastric inflammation and premalignant lesions in INS-GAS mice with the modulation of gastrointestinal microbiota.
     Helicobacter. 2022 May 9:e12898. doi: 10.1111/hel.12898.
     PubMed     Abstract available
     
     
     
122. PHUNG HTT, Deenonpoe R, Suttiprapa S, Mairiang E, et al
     Persistent advanced periductal fibrosis is associated with cagA-positive Helicobacter pylori infection in post-praziquantel treatment of opisthorchiasis.
     Helicobacter. 2022 May 9:e12897. doi: 10.1111/hel.12897.
     PubMed     Abstract available
     
     
     April 2022
123. SAIF N, Jensen N, Farrar E, Blackstone S, et al
     Prevalence of Helicobacter pylori infection among resettled refugees presenting to a family medicine clinic in the United States.
     Helicobacter. 2022 Apr 28:e12894. doi: 10.1111/hel.12894.
     PubMed     Abstract available
     
     
     
124. HU Y, Xu X, Ouyang YB, He C, et al
     Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study.
     Helicobacter. 2022 Apr 25:e12896. doi: 10.1111/hel.12896.
     PubMed     Abstract available
     
     
     
125. LI C, Lu C, Gong L, Liu J, et al
     SHP2/SPI1axis promotes glycolysis and the inflammatory response of macrophages in Helicobacter pylori-induced pediatric gastritis.
     Helicobacter. 2022 Apr 19:e12895. doi: 10.1111/hel.12895.
     PubMed     Abstract available
     
     
     
126. JIANG F, Guo CG, Cheung KS, Li B, et al
     Age of eradication and failure rates of clarithromycin-containing triple therapy for Helicobacter pylori: A 15-year population-based study.
     Helicobacter. 2022 Apr 12:e12893. doi: 10.1111/hel.12893.
     PubMed     Abstract available
     
     
     
127. CHUA BQY, Chong VWS, Teng TZJ, Chia CTW, et al
     Does technology-enhanced communication improve Helicobacter pylori eradication outcomes?-A meta-analysis.
     Helicobacter. 2022 Apr 1:e12890. doi: 10.1111/hel.12890.
     PubMed     Abstract available
     
     
     
128. SONG Z, Chen Y, Lu H, Zeng Z, et al
     Diagnosis and treatment of Helicobacter pylori infection by physicians in China: A nationwide cross-sectional study.
     Helicobacter. 2022 Apr 1:e12889. doi: 10.1111/hel.12889.
     PubMed     Abstract available
     
     
     March 2022
129. KOWADA A, Asaka M
     Economic and health impacts of Helicobacter pylori eradication strategy for the treatment of peptic ulcer disease: A cost-effectiveness analysis.
     Helicobacter. 2022 Mar 27:e12886. doi: 10.1111/hel.12886.
     PubMed     Abstract available
     
     
     
130. HSIEH H, Yang HB, Sheu BS, Yang YJ, et al
     Atrophic gastritis in Helicobacter pylori-infected children.
     Helicobacter. 2022 Mar 20:e12885. doi: 10.1111/hel.12885.
     PubMed     Abstract available
     
     
     
131. POLIVANOVA TV, Malaty H, Vshivkov VA
     Epidemiology Helicobacter pylori infection in children in the Tyva Republic (Russia).
     Helicobacter. 2022 Mar 13:e12882. doi: 10.1111/hel.12882.
     PubMed     Abstract available
     
     
     
132. KOUNTOURAS J, Kazakos E, Polyzos SA, Chatzopoulos D, et al
     GM-CSF as a potential candidate of a vaccine-induced reduction of Helicobacter pylori infection.
     Helicobacter. 2022 Mar 7:e12884. doi: 10.1111/hel.12884.
     PubMed    
     
     
     
133. YOKOTA K, Osaki T, Hayashi S, Yokota SI, et al
     Establishment of a reference panel of Helicobacter pylori strains for antimicrobial susceptibility testing.
     Helicobacter. 2022 Mar 7:e12874. doi: 10.1111/hel.12874.
     PubMed     Abstract available
     
     
     
134. MORAIS S, Costa A, Albuquerque G, Araujo N, et al
     "True" Helicobacter pylori infection and non-cardia gastric cancer: A pooled analysis within the Stomach Cancer Pooling (StoP) Project.
     Helicobacter. 2022 Mar 2:e12883. doi: 10.1111/hel.12883.
     PubMed     Abstract available
     
     
     February 2022
135. EL HAFA F, Wang T, Ndifor VM, Jin G, et al
     Association between Helicobacter pylori antibodies determined by multiplex serology and gastric cancer risk: A meta-analysis.
     Helicobacter. 2022 Feb 24:e12881. doi: 10.1111/hel.12881.
     PubMed     Abstract available
     
     
     
136. ZHOU BG, Yan XL, Wan LY, Zhang Q, et al
     Effect of enhanced patient instructions on Helicobacter pylori eradication: A systematic review and meta-analysis of randomized controlled trials.
     Helicobacter. 2022 Feb 18:e12869. doi: 10.1111/hel.12869.
     PubMed     Abstract available
     
     
     
137. LI H, Shen Y, Song X, Tang X, et al
     Need for standardization and harmonization of Helicobacter pylori antimicrobial susceptibility testing.
     Helicobacter. 2022 Feb 12:e12873. doi: 10.1111/hel.12873.
     PubMed     Abstract available
     
     
     
138. ZHA J, Li YY, Qu JY, Yang XX, et al
     Effects of enhanced education for patients with the Helicobacter pylori infection: A systematic review and meta-analysis.
     Helicobacter. 2022 Feb 12:e12880. doi: 10.1111/hel.12880.
     PubMed     Abstract available
     
     
     
139. SHAO QQ, Yu XC, Yu M, Ma J, et al
     Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial.
     Helicobacter. 2022 Feb 12:e12876. doi: 10.1111/hel.12876.
     PubMed     Abstract available
     
     
     
140. LI Y, Huang Z, Shang Y, Xie X, et al
     Exploration of the molecular mechanisms underlying the antibiotic resistance of Helicobacter pylori: A whole-genome sequencing-based study in Southern China.
     Helicobacter. 2022 Feb 6:e12879. doi: 10.1111/hel.12879.
     PubMed     Abstract available
     
     
     
141. SHI Y, Zheng H, Wang M, Ding S, et al
     Influence of Helicobacter pylori infection on PD-1/PD-L1 blockade therapy needs more attention.
     Helicobacter. 2022 Feb 3:e12878. doi: 10.1111/hel.12878.
     PubMed     Abstract available
     
     
     January 2022
142. QIANG L, Hu J, Tian M, Li Y, et al
     Extracellular vesicles from helicobacter pylori-infected cells and helicobacter pylori outer membrane vesicles in atherosclerosis.
     Helicobacter. 2022 Jan 31:e12877. doi: 10.1111/hel.12877.
     PubMed     Abstract available
     
     
     
143. VAILLANT L, Oster P, McMillan B, Orozco Fernandez E, et al
     GM-CSF is key in the efficacy of vaccine-induced reduction of Helicobacter pylori infection.
     Helicobacter. 2022 Jan 29:e12875. doi: 10.1111/hel.12875.
     PubMed     Abstract available
     
     
     
144. DI MARIO F, Crafa P, Barchi A, Franzoni L, et al
     Pepsinogen II in gastritis and Helicobacter pylori infection.
     Helicobacter. 2022 Jan 8:e12872. doi: 10.1111/hel.12872.
     PubMed     Abstract available
     
     
     
145. XU C, Wu Y, Xu S
     Association between Helicobacter pylori infection and growth outcomes in children: A meta-analysis.
     Helicobacter. 2022 Jan 8:e12861. doi: 10.1111/hel.12861.
     PubMed     Abstract available
     
     
     
146. CIFUENTES SG, Prado MB, Fornasini M, Cohen H, et al
     Saccharomyces boulardii CNCM I-745 supplementation modifies the fecal resistome during Helicobacter pylori eradication therapy.
     Helicobacter. 2022 Jan 6:e12870. doi: 10.1111/hel.12870.
     PubMed     Abstract available
     
     
     December 2021
147. WANG L, Yao H, Tong T, Lau K, et al
     Dynamic changes in antibiotic resistance genes and gut microbiota after Helicobacter pylori eradication therapies.
     Helicobacter. 2021 Dec 30:e12871. doi: 10.1111/hel.12871.
     PubMed     Abstract available
     
     
     
148. HUANG JG, Lim SYS, Aw MM, Quak SH, et al
     Antibiotic resistance patterns and therapeutic outcomes of pediatric Helicobacter pylori infection in a high-migrant Singaporean cohort.
     Helicobacter. 2021 Dec 27:e12868. doi: 10.1111/hel.12868.
     PubMed     Abstract available
     
     
     November 2021
149. SHI H, Li Y, Dong C, Si G, et al
     Helicobacter pylori infection and the progression of atherosclerosis: A systematic review and meta-analysis.
     Helicobacter. 2021 Nov 28:e12865. doi: 10.1111/hel.12865.
     PubMed     Abstract available
     
     
     
150. FERREIRA EO, Lagace-Wiens P, Klein J
     Campylobacter concisus gastritis masquerading as Helicobacter pylori on gastric biopsy.
     Helicobacter. 2021 Nov 24:e12864. doi: 10.1111/hel.12864.
     PubMed     Abstract available
     
     
     
151. MURATA M, Sugimoto M, Miyamoto S, Kawai T, et al
     Long-term improvement in constipation-related symptoms after Helicobacter pylori eradication therapy.
     Helicobacter. 2021 Nov 17:e12863. doi: 10.1111/hel.12863.
     PubMed     Abstract available
     
     
     
152. ZAGARI RM, Romano M, Frazzoni L, Marasco G, et al
     Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in Italy: A Survey of the Italian Federation of Digestive Diseases - FISMAD.
     Helicobacter. 2021 Nov 11:e12862. doi: 10.1111/hel.12862.
     PubMed     Abstract available
     
     
     October 2021
153. YU J, Yang P, Qin X, Li C, et al
     Impact of smoking on the eradication of Helicobacter pylori.
     Helicobacter. 2021 Oct 27:e12860. doi: 10.1111/hel.12860.
     PubMed     Abstract available
     
     
     
154. CHEN MJ, Chen CC, Huang YC, Tseng CC, et al
     The efficacy of Lactobacillus acidophilus and rhamnosus in the reduction of bacterial load of Helicobacter pylori and modification of gut microbiota-a double-blind, placebo-controlled, randomized trial.
     Helicobacter. 2021 Oct 27:e12857. doi: 10.1111/hel.12857.
     PubMed     Abstract available
     
     
     
155. YANG C, Liang L, Lv P, Liu L, et al
     Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication: A randomized double-blind placebo-controlled trial.
     Helicobacter. 2021 Oct 10:e12856. doi: 10.1111/hel.12856.
     PubMed     Abstract available
     
     
     
156. BENEJAT L, Ducournau A, Domingues-Martins C, Lecoeur M, et al
     Adaptation of an in-house PCR for the detection of Helicobacter pylori and the mutations associated with macrolide resistance into ready-to-use PCR microwell strips.
     Helicobacter. 2021 Oct 10:e12855. doi: 10.1111/hel.12855.
     PubMed     Abstract available
     
     
     
157. LAPIDOT Y, Reshef L, Cohen D, Muhsen K, et al
     Helicobacter pylori and the intestinal microbiome among healthy school-age children.
     Helicobacter. 2021 Oct 7:e12854. doi: 10.1111/hel.12854.
     PubMed     Abstract available
     
     
     September 2021
158. VARMA M, Yoe J
     Importance of testing for Helicobacter pylori in patients with immune thrombocytopenia.
     Helicobacter. 2021 Sep 22:e12850. doi: 10.1111/hel.12850.
     PubMed    
     
     
     
159. LUCERO Y, Lagomarcino AJ, Torres JP, Roessler P, et al
     Effect of Helicobacter pylori eradication therapy on clinical and laboratory biomarkers associated with gastric damage in healthy school-aged children: A randomized non-blinded trial.
     Helicobacter. 2021 Sep 15:e12853. doi: 10.1111/hel.12853.
     PubMed     Abstract available
     
     
     
160. ZHAO H, Yan P, Zhang N, Feng L, et al
     The recurrence rate of Helicobacter pylori in recent 10 years: A systematic review and meta-analysis.
     Helicobacter. 2021 Sep 12:e12852. doi: 10.1111/hel.12852.
     PubMed     Abstract available
     
     
     
161. CHEN HY, Hu Y, Xu XB, Zhou YA, et al
     Upregulation of oncogene Activin A receptor type I by Helicobacter pylori infection promotes gastric intestinal metaplasia via regulating CDX2.
     Helicobacter. 2021 Sep 7:e12849. doi: 10.1111/hel.12849.
     PubMed     Abstract available
     
     
     
162. SUZUKI S, Gotoda T, Takano C, Horii T, et al
     Long term impact of vonoprazan-based Helicobacter pylori treatment on gut microbiota and its relation to post-treatment body weight changes.
     Helicobacter. 2021 Sep 6:e12851. doi: 10.1111/hel.12851.
     PubMed     Abstract available
     
     
     August 2021
163. YUAN Z, Xiao S, Li S, Suo B, et al
     The impact of Helicobacter pylori infection, eradication therapy, and probiotics intervention on gastric microbiota in young adults.
     Helicobacter. 2021 Aug 26:e12848. doi: 10.1111/hel.12848.
     PubMed     Abstract available
     
     
     
164. YAO X, Xiao S, Zhou L
     Integrative proteomic and metabolomic analyses reveal the mechanism by which bismuth enables Helicobacter pylori eradication.
     Helicobacter. 2021 Aug 20:e12846. doi: 10.1111/hel.12846.
     PubMed     Abstract available
     
     
     
165. LEE JW, Kim N, Nam RH, Jang JY, et al
     Favorable outcomes of rescue second- or third-line culture-based Helicobacter pylori eradication treatment in areas of high antimicrobial resistance.
     Helicobacter. 2021 Aug 12:e12844. doi: 10.1111/hel.12844.
     PubMed     Abstract available
     
     
     
166. HSU PI, Tsay FW, Kao JY, Peng NJ, et al
     Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection.
     Helicobacter. 2021 Aug 12:e12840. doi: 10.1111/hel.12840.
     PubMed     Abstract available
     
     
     
167. GUO R, Wu S, Guan L, Xie Y, et al
     Dietary multivalent anti-Helicobacter pylori immunoglobulin Y significantly increase the H. pylori eradication and improve the clinical symptoms in patients.
     Helicobacter. 2021 Aug 11:e12843. doi: 10.1111/hel.12843.
     PubMed     Abstract available
     
     
     July 2021
168. GONG L, El-Omar EM
     Application of molecular techniques in Helicobacter pylori detection: limitations and improvements.
     Helicobacter. 2021 Jul 31:e12841. doi: 10.1111/hel.12841.
     PubMed    
     
     
     
169. OUYANG Y, Zhang W, Huang Y, Wang Y, et al
     Effect of Helicobacter pylori eradication on hyperplastic gastric polyps: A systematic review and meta-analysis.
     Helicobacter. 2021 Jul 31:e12838. doi: 10.1111/hel.12838.
     PubMed     Abstract available
     
     
     
170. LI N, Xu X, Yang H, Wang H, et al
     Activation of Aquaporin 5 by carcinogenic Helicobacter pylori infection promotes epithelial-mesenchymal transition via the MEK/ERK pathway.
     Helicobacter. 2021 Jul 30:e12842. doi: 10.1111/hel.12842.
     PubMed     Abstract available
     
     
     
171. ZHAO J, Zou Y, Li K, Huang X, et al
     Doxycycline and minocycline in Helicobacter pylori treatment: A systematic review and meta-analysis.
     Helicobacter. 2021 Jul 28:e12839. doi: 10.1111/hel.12839.
     PubMed     Abstract available
     
     
     
172. ZOU PY, Hu J, Zhao JT, Zhao Z, et al
     10-Day and 14-day high-dose dual therapy for the treatment of Helicobacter pylori: A propensity score matching analysis.
     Helicobacter. 2021 Jul 28:e12833. doi: 10.1111/hel.12833.
     PubMed     Abstract available
     
     
     
173. KOWADA A, Asaka M
     Economic and health impacts of introducing Helicobacter pylori eradication strategy into national gastric cancer policy in Japan: A cost-effectiveness analysis.
     Helicobacter. 2021 Jul 18:e12837. doi: 10.1111/hel.12837.
     PubMed     Abstract available
     
     
     
174. GUNATHILAKE M, Lee J, Choi IJ, Kim YI, et al
     Association between bacteria other than Helicobacter pylori and the risk of gastric cancer.
     Helicobacter. 2021 Jul 15:e12836. doi: 10.1111/hel.12836.
     PubMed     Abstract available
     
     
     
175. OUYANG Y, Zhu Z, Huang L, Zeng C, et al
     Research Trends on Clinical Helicobacter pylori Eradication: A Bibliometric Analysis from 1983 to 2020.
     Helicobacter. 2021 Jul 13:e12835. doi: 10.1111/hel.12835.
     PubMed     Abstract available
     
     
     
176. GUNARATNE AW, Hamblin H, Clancy A, Magat AJMC, et al
     Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study.
     Helicobacter. 2021 Jul 10:e12830. doi: 10.1111/hel.12830.
     PubMed     Abstract available
     
     
     
177. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
     cagA+ Helicobacter pylori infection and N-nitrosodimethylamine and cholangiocarcinoma.
     Helicobacter. 2021 Jul 8:e12834. doi: 10.1111/hel.12834.
     PubMed    
     
     
     
178. MA H, Zhao XH, Zhang LL, Wu LM, et al
     Application of WeChat platform in the management of patients infected with Helicobacter pylori.
     Helicobacter. 2021 Jul 7:e12832. doi: 10.1111/hel.12832.
     PubMed     Abstract available
     
     
     
179. HE Y, Ning J, Li B, Guo H, et al
     IL-9 contributes to the host immune response against Helicobacter pylori and helps limit infection in a Mouse Model.
     Helicobacter. 2021 Jul 7:e12827. doi: 10.1111/hel.12827.
     PubMed     Abstract available
     
     
     June 2021
180. TSAI CF, Chen MH, Wang YP, Liu PY, et al
     Increased risk of short-term depressive disorder after Helicobacter pylori eradication: A population-based nested cohort study.
     Helicobacter. 2021 Jun 11:e12824. doi: 10.1111/hel.12824.
     PubMed     Abstract available
     
     
     
181. QIU E, Jin S, Xiao Z, Chen Q, et al
     CRISPR-based detection of Helicobacter pylori in stool samples.
     Helicobacter. 2021 Jun 11:e12828. doi: 10.1111/hel.12828.
     PubMed     Abstract available
     
     
     
182. KOTILEA K, Cadranel S, Salame A, Nguyen J, et al
     Efficacy and safety of bismuth-based quadruple therapy for Helicobacter pylori eradication in children.
     Helicobacter. 2021 Jun 7:e12825. doi: 10.1111/hel.12825.
     PubMed     Abstract available
     
     
     May 2021
183. MONZANI A, Lionetti P, Rabbone I, Lionetti E, et al
     The best is the enemy of the good: Time for a biopsy-sparing approach for Helicobacter pylori diagnosis and treatment in children in the COVID-19 era?
     Helicobacter. 2021 May 28:e12826. doi: 10.1111/hel.12826.
     PubMed    
     
     
     
184. DANGTAKOT R, Intuyod K, Chamgramol Y, Pairojkul C, et al
     CagA(+) Helicobacter pylori infection and N-nitrosodimethylamine administration induce cholangiocarcinoma development in hamsters.
     Helicobacter. 2021 May 24:e12817. doi: 10.1111/hel.12817.
     PubMed     Abstract available
     
     
     
185. LI C, Shi Y, Suo B, Tian X, et al
     PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta-analysis.
     Helicobacter. 2021 May 17:e12816. doi: 10.1111/hel.12816.
     PubMed     Abstract available
     
     
     
186. TSUKADAIRA T, Hayashi S, Ota H, Kobayashi N, et al
     Acute gastric mucosal lesions caused by acute infection of non-Helicobacter pylori Helicobacter: a case report.
     Helicobacter. 2021 May 11:e12814. doi: 10.1111/hel.12814.
     PubMed     Abstract available
     
     
     
187. ZHANG Z, Chen S, Fan M, Ruan G, et al
     Helicobacter pylori induces gastric cancer via down-regulating miR-375 to inhibit dendritic cell maturation.
     Helicobacter. 2021 May 3:e12813. doi: 10.1111/hel.12813.
     PubMed     Abstract available
     
     
     April 2021
188. HERNANDEZ C, Toledo-Stuardo K, Garcia-Gonzalez P, Garrido-Tapia M, et al
     Heat-killed Helicobacter pylori upregulates NKG2D ligands expression on gastric adenocarcinoma cells via Toll-like receptor 4.
     Helicobacter. 2021 Apr 29:e12812. doi: 10.1111/hel.12812.
     PubMed     Abstract available
     
     
     
189. TSUKADAIRA T, Hayashi S, Ota H, Kobayashi N, et al
     Prevalence, clinical features, and esophagogastroduodenoscopy (EGD) findings of non-Helicobacter pylori Helicobacter infection: A study of 50 cases at a single facility in Japan.
     Helicobacter. 2021 Apr 27:e12811. doi: 10.1111/hel.12811.
     PubMed     Abstract available
     
     
     
190. WANG X, Shu X, Li Q, Li Y, et al
     Prevalence and risk factors of Helicobacter pylori infection in Wuwei, a high-risk area for gastric cancer in northwest China: An all-ages population-based cross-sectional study.
     Helicobacter. 2021 Apr 27:e12810. doi: 10.1111/hel.12810.
     PubMed     Abstract available
     
     
     
191. ZHOU Y, Ye Z, Wang Y, Huang Z, et al
     Long-term changes in the gut microbiota after triple therapy, sequential therapy, bismuth quadruple therapy and concomitant therapy for Helicobacter pylori eradication in Chinese children.
     Helicobacter. 2021 Apr 25:e12809. doi: 10.1111/hel.12809.
     PubMed     Abstract available
     
     
     
192. LI SY, Li J, Dong XH, Teng GG, et al
     The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing.
     Helicobacter. 2021 Apr 16:e12804. doi: 10.1111/hel.12804.
     PubMed     Abstract available
     
     
     
193. XIE W, Zhao W, Zou Z, Kong L, et al
     Oral multivalent epitope vaccine, based on UreB, HpaA, CAT, and LTB, for prevention and treatment of Helicobacter pylori infection in C57BL / 6 mice.
     Helicobacter. 2021 Apr 12:e12807. doi: 10.1111/hel.12807.
     PubMed     Abstract available
     
     
     
194. DO AD, Chang CC, Su CH, Hsu YM, et al
     Lactobacillus rhamnosus JB3 inhibits Helicobacter pylori infection through multiple molecular actions.
     Helicobacter. 2021 Apr 11:e12806. doi: 10.1111/hel.12806.
     PubMed     Abstract available
     
     
     
195. TURNER KO, Lindberg GM, Genta RM
     Gastric granulomas and Helicobacter pylori: An incidental relationship.
     Helicobacter. 2021 Apr 11:e12805. doi: 10.1111/hel.12805.
     PubMed     Abstract available
     
     
     
196. YORGUC E, Gulerman HF, Kalkan IH, Guven B, et al
     Comparison of clinical outcomes and FOXP3, IL-17A responses in Helicobacter pylori infection in children versus adults.
     Helicobacter. 2021 Apr 5:e12795. doi: 10.1111/hel.12795.
     PubMed     Abstract available
     
     
     
197. KUBOTA-AIZAWA S, Matsubara Y, Kanemoto H, Mimuro H, et al
     Transmission of Helicobacter pylori between a human and two dogs: A case report.
     Helicobacter. 2021 Apr 5:e12798. doi: 10.1111/hel.12798.
     PubMed     Abstract available
     
     
     March 2021
198. LI Y, Li X, Tan Z
     An overview of traditional Chinese medicine therapy for Helicobacter pylori-related gastritis.
     Helicobacter. 2021 Mar 25:e12799. doi: 10.1111/hel.12799.
     PubMed     Abstract available
     
     
     
199. CHIANG TH, Chen CC, Tseng PH, Liou JM, et al
     Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study.
     Helicobacter. 2021 Mar 19:e12801. doi: 10.1111/hel.12801.
     PubMed     Abstract available
     
     
     
200. HEFFLEY JD, Zubarik R
     A standardized protocol improves testing rates for Helicobacter Pylori among inpatients with peptic ulcer disease.
     Helicobacter. 2021 Mar 15:e12800. doi: 10.1111/hel.12800.
     PubMed     Abstract available
     
     
     
201. MARUBASHI K, Takakusagi S, Yokoyama Y, Kizawa K, et al
     Changes of (18) F-fluoro-2-deoxyglucose position-emission tomography findings by the eradication of Helicobacter pylori in the stomach.
     Helicobacter. 2021 Mar 8:e12797. doi: 10.1111/hel.12797.
     PubMed     Abstract available
     
     
     
202. ZHAO JB, Yuan L, Yu XC, Shao QQ, et al
     Whole family-based Helicobacter pylori eradication is a superior strategy to single-infected patient treatment approach: A systematic review and meta-analysis.
     Helicobacter. 2021 Mar 6:e12793. doi: 10.1111/hel.12793.
     PubMed     Abstract available
     
     
     
203. JAIN U, Saxena K, Chauhan N
     Helicobacter pylori induced reactive oxygen Species: A new and developing platform for detection.
     Helicobacter. 2021 Mar 5:e12796. doi: 10.1111/hel.12796.
     PubMed     Abstract available
     
     
     
204. TENG TZJ, Sudharsan M, Yau JWK, Tan W, et al
     Helicobacter pylori knowledge and perception among multi-ethnic Asians.
     Helicobacter. 2021 Mar 3:e12794. doi: 10.1111/hel.12794.
     PubMed     Abstract available
     
     
     
205. KIM YJ, Chung WC, Kim DB
     Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection.
     Helicobacter. 2021 Mar 1:e12792. doi: 10.1111/hel.12792.
     PubMed     Abstract available
     
     
     February 2021
206. HUANG Y, Ding Y, Xu H, Shen C, et al
     Effects of sodium butyrate supplementation on inflammation, gut microbiota, and short-chain fatty acids in Helicobacter pylori-infected mice.
     Helicobacter. 2021 Feb 20:e12785. doi: 10.1111/hel.12785.
     PubMed     Abstract available
     
     
     
207. XIE M, Li Q, Zhang B, Zhang Q, et al
     Preliminary single-center experience of Helicobacter pylori eradication among the liver transplant recipients.
     Helicobacter. 2021 Feb 18:e12791. doi: 10.1111/hel.12791.
     PubMed     Abstract available
     
     
     
208. GANTUYA B, El Serag HB, Saruuljavkhlan B, Azzaya D, et al
     Advantage of 16S rRNA amplicon sequencing in Helicobacter pylori diagnosis.
     Helicobacter. 2021 Feb 17:e12790. doi: 10.1111/hel.12790.
     PubMed     Abstract available
     
     
     
209. LEE BE, Kim JS, Kim BW, Kim JH, et al
     Consistency of Helicobacter pylori eradication rates of first-line concomitant and sequential therapies in Korea: A nationwide multicenter retrospective study for the last 10 years.
     Helicobacter. 2021 Feb 17:e12780. doi: 10.1111/hel.12780.
     PubMed     Abstract available
     
     
     
210. WU ZF, Zou K, Xiang CJ, Jin ZJ, et al
     Helicobacter pylori infection is associated with the co-occurrence of bacteria in the oral cavity and the gastric mucosa.
     Helicobacter. 2021 Feb 17:e12786. doi: 10.1111/hel.12786.
     PubMed     Abstract available
     
     
     
211. YANG KY, Kao CY, Su MS, Wang S, et al
     Glycosyltransferase Jhp0106 (PseE) contributes to flagellin maturation in Helicobacter pylori.
     Helicobacter. 2021 Feb 15:e12787. doi: 10.1111/hel.12787.
     PubMed     Abstract available
     
     
     
212. LACOUT C, Savey L, Bourguiba R, Giurgea I, et al
     "Helicobacter pylori in familial mediterranean fever: A series of 120 patients from literature and from france".
     Helicobacter. 2021 Feb 15:e12789. doi: 10.1111/hel.12789.
     PubMed     Abstract available
     
     
     
213. ETO H, Suzuki S, Kusano C, Ikehara H, et al
     Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy.
     Helicobacter. 2021 Feb 12:e12788. doi: 10.1111/hel.12788.
     PubMed     Abstract available
     
     
     
214. HU Y, Ouyang Y, Zhu Y, Lu NH, et al
     Reverse hybrid therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
     Helicobacter. 2021 Feb 3:e12784. doi: 10.1111/hel.12784.
     PubMed     Abstract available
     
     
     January 2021
215. PARK Y, Kim TJ, Lee H, Yoo H, et al
     Eradication of Helicobacter pylori infection decreases risk for dyslipidemia: A cohort study.
     Helicobacter. 2021 Jan 28:e12783. doi: 10.1111/hel.12783.
     PubMed     Abstract available
     
     
     
216. DOMANOVICH-ASOR T, Craddock HA, Motro Y, Khalfin B, et al
     Unraveling antimicrobial resistance in Helicobacter pylori: Global resistome meets global phylogeny.
     Helicobacter. 2021 Jan 25:e12782. doi: 10.1111/hel.12782.
     PubMed     Abstract available
     
     
     
217. SONG X, Cai C, Jin Q, Chen X, et al
     The efficacy of Helicobacter pylori eradication in diabetics and its effect on glycemic control: A systematic review and meta-analysis.
     Helicobacter. 2021 Jan 19:e12781. doi: 10.1111/hel.12781.
     PubMed     Abstract available
     
     
     
218. WEN Y, Huang H, Tang T, Yang H, et al
     AI-2 represses CagA expression and bacterial adhesion, attenuating the Helicobacter pylori-induced inflammatory response of gastric epithelial cells.
     Helicobacter. 2021 Jan 5:e12778. doi: 10.1111/hel.12778.
     PubMed     Abstract available
     
     
     
219. MUNOZ AB, Trespalacios-Rangel AA, Vale FF
     An American lineage of Helicobacter pylori prophages found in Colombia.
     Helicobacter. 2021 Jan 5:e12779. doi: 10.1111/hel.12779.
     PubMed     Abstract available
     
     
     
220. JUNG K, Kim DH, Seo HI, Gong EJ, et al
     Efficacy of eradication therapy in Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: A meta-analysis.
     Helicobacter. 2021 Jan 5:e12774. doi: 10.1111/hel.12774.
     PubMed     Abstract available
     
     
     December 2020
221. XUE Q, Li X, Li Y, Xu J, et al
     Dialogue between gastrointestinal tract and skin: New insights into the Helicobacter pylori and atopic dermatitis.
     Helicobacter. 2020 Dec 23:e12771. doi: 10.1111/hel.12771.
     PubMed     Abstract available
     
     
     
222. QARIA MA, Qumar S, Sepe LP, Ahmed N, et al
     Cholesterol glucosylation-based survival strategy in Helicobacter pylori.
     Helicobacter. 2020 Dec 23:e12777. doi: 10.1111/hel.12777.
     PubMed     Abstract available
     
     
     
223. KAKIUCHI T, Matsuo M, Endo H, Sakata Y, et al
     Gastrointestinal adverse reactions reduce the success rate of Helicobacter pylori eradication therapy: A multicenter prospective cohort study.
     Helicobacter. 2020 Dec 23:e12776. doi: 10.1111/hel.12776.
     PubMed     Abstract available
     
     
     
224. JUKIC I, Vukovic J, Rusic D, Bozic J, et al
     Adherence to Maastricht V/Florence consensus report for the management of Helicobacter pylori infection among primary care physicians and medical students in Croatia: A cross-sectional study.
     Helicobacter. 2020 Dec 23:e12775. doi: 10.1111/hel.12775.
     PubMed     Abstract available
     
     
     
225. BANGA NDZOUBOUKOU JL, Lei Q, Ullah N, Zhang Y, et al
     Helicobacter pylori adhesins: HpaA a potential antigen in experimental vaccines for H. pylori.
     Helicobacter. 2020 Dec 1:e12758. doi: 10.1111/hel.12758.
     PubMed     Abstract available
     
     
     November 2020
226. CEN Q, Gao T, Ren Y, Lu X, et al
     Immune evaluation of a Saccharomyces cerevisiae-based oral vaccine against Helicobacter pylori in mice.
     Helicobacter. 2020 Nov 20:e12772. doi: 10.1111/hel.12772.
     PubMed     Abstract available
     
     
     
227. GRAHAM DY, Megraud F
     Classification system for Helicobacter pylori therapies: Compared and contrasted to traditional infectious disease therapy.
     Helicobacter. 2020 Nov 18:e12773. doi: 10.1111/hel.12773.
     PubMed    
     
     
     
228. SINGH H, Chung H, Awan I, Mone A, et al
     Designing strategies for eradication of Helicobacter pylori based on prevalence patterns of infection and antibiotic resistance in a low-income, medically underserved community in the United States.
     Helicobacter. 2020 Nov 9:e12769. doi: 10.1111/hel.12769.
     PubMed     Abstract available
     
     
     October 2020
229. PIH GY, Choi KD, Gong EJ, Na HK, et al
     Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection.
     Helicobacter. 2020 Oct 28:e12759. doi: 10.1111/hel.12759.
     PubMed     Abstract available
     
     
     
230. MEGRAUD F, Alix C, Charron P, Benejat L, et al
     Survey of the antimicrobial resistance of Helicobacter pylori in France in 2018 and evolution during the previous 5 years.
     Helicobacter. 2020 Oct 22:e12767. doi: 10.1111/hel.12767.
     PubMed     Abstract available
     
     
     
231. KE H, Li J, Lu B, Yang C, et al
     The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth-based quadruple therapy.
     Helicobacter. 2020 Oct 21:e12768. doi: 10.1111/hel.12768.
     PubMed     Abstract available
     
     
     
232. QUMAR S, Nguyen TH, Nahar S, Sarker N, et al
     A comparative whole genome analysis of Helicobacter pylori from a human dense South Asian setting.
     Helicobacter. 2020 Oct 18:e12766. doi: 10.1111/hel.12766.
     PubMed     Abstract available
     
     
     
233. MIYATA E, Kudo T, Ikuse T, Tokita K, et al
     Eradication therapy for Helicobacter pylori infection based on the antimicrobial susceptibility test in children: A single-center study over 12 years.
     Helicobacter. 2020 Oct 18:e12764. doi: 10.1111/hel.12764.
     PubMed     Abstract available
     
     
     
234. HOFREUTER D, Behrendt J, Franz A, Meyer J, et al
     Antimicrobial resistance of Helicobacter pylori in an eastern German region.
     Helicobacter. 2020 Oct 17:e12765. doi: 10.1111/hel.12765.
     PubMed     Abstract available
     
     
     
235. SONG Z, Zhou L, Xue Y, Suo B, et al
     A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
     Helicobacter. 2020 Oct 11:e12762. doi: 10.1111/hel.12762.
     PubMed     Abstract available
     
     
     
236. WANG B, Yu M, Zhang R, Chen S, et al
     A meta-analysis of the association between Helicobacter pylori infection and risk of atherosclerotic cardiovascular disease.
     Helicobacter. 2020 Oct 7:e12761. doi: 10.1111/hel.12761.
     PubMed     Abstract available
     
     
     
237. ALVAREZ CS, Florio AA, Butt J, Rivera-Andrade A, et al
     Associations between Helicobacter pylori with nonalcoholic fatty liver disease and other metabolic conditions in Guatemala.
     Helicobacter. 2020 Oct 2:e12756. doi: 10.1111/hel.12756.
     PubMed     Abstract available
     
     
     
238. HUANG JW, Xie C, Niu Z, He LJ, et al
     The relation between Helicobacter pylori immunoglobulin G seropositivity and leukocyte telomere length in US adults from NHANES 1999-2000.
     Helicobacter. 2020 Oct 1:e12760. doi: 10.1111/hel.12760.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Peptic Ulcer is free of charge.